Informed by a drug screen approach to define synthetic lethal interaction for the novel TRAP1 inhibitor, gamitrinib, we validated whether or not global or selective HDAC inhibitors induce synergistic reduction of cellular viability in relevant model systems of human glioblastoma (Figure 1A–D). Here, HDAC9 is linked to glioblastoma.